State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.
Arch Microbiol. 2024 Aug 14;206(9):379. doi: 10.1007/s00203-024-04106-0.
Multidrug-resistant Klebsiella pneumoniae (MDR-KP) poses a significant challenge in global healthcare, underscoring the urgency for innovative therapeutic approaches. Phage therapy emerges as a promising strategy amidst rising antibiotic resistance, emphasizing the crucial need to identify and characterize effective phage resources for clinical use. In this study, we introduce a novel lytic phage, RCIP0100, distinguished by its classification into the Chaoyangvirus genus and Fjlabviridae family based on International Committee on Taxonomy of Viruses (ICTV) criteria due to low genetic similarity to known phage families. Our findings demonstrate that RCIP0100 exhibits broad lytic activity against 15 out of 27 tested MDR-KP strains, including diverse profiles such as carbapenem-resistant K. pneumoniae (CR-KP). This positions phage RCIP0100 as a promising candidate for phage therapy. Strains resistant to RCIP0100 also showed increased susceptibility to various antibiotics, implying the potential for synergistic use of RCIP0100 and antibiotics as a strategic countermeasure against MDR-KP.
多药耐药肺炎克雷伯菌（MDR-KP）在全球医疗保健领域构成重大挑战，凸显出需要创新治疗方法的紧迫性。噬菌体治疗作为一种有前途的策略，在抗生素耐药性不断上升的情况下应运而生，强调了迫切需要识别和鉴定用于临床应用的有效噬菌体资源。在这项研究中，我们介绍了一种新型裂解噬菌体 RCIP0100，根据国际病毒分类委员会（ICTV）的标准，由于与已知噬菌体家族的遗传相似度较低，它被归类为朝阳病毒属和 Fjlabviridae 科。我们的研究结果表明，RCIP0100 对 27 株测试的 MDR-KP 菌株中的 15 株具有广泛的裂解活性，包括碳青霉烯类耐药肺炎克雷伯菌（CR-KP）等多种耐药谱。这使得噬菌体 RCIP0100 成为噬菌体治疗的有前途的候选者。对 RCIP0100 有抗性的菌株也显示出对各种抗生素的敏感性增加，这意味着 RCIP0100 与抗生素联合使用作为对抗 MDR-KP 的策略性对策具有潜在协同作用。
